Government policy and regulations have been our largest levers in the struggle towards reversing climate change and avoiding ecological damage. The second line of battle is sheer scientific innovation born from basic research. Third in battle - and still impressive - is private innovation from companies looking at the long game.

As the pandemic stubbornly continues to challenge us, biotechnology has nonetheless made enormous strides. DNA sequencing costs have plummeted, while genetic engineering power has exploded. The very race for vaccines has led to new technologies in discovery, screening, and delivery previously undreamt of.

Building better health could be considered a global motto.

Discovered in 2006, and awarded the Nobel Prize in 2012, induced pluripotent stem cells (iPSCs) have been waiting in the wings of the theater of drug development. The global iPSC market will see steady growth over the next few years, growing 9.2% annually to reach $3.8 billion by 2024.

Remdesivir—the experimental COVID19 treatment developed by Gilead Sciences—is having its moment.

Robots have historically been designed to serve, be it in industrial, military, medical or other settings.
Emerging now is a new category of robot: Social.